Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Hold” by Analysts
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned an average rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target […]
More Stories
Renaissance Technologies LLC Makes New Investment in Pacer US Cash Cows 100 ETF (BATS:COWZ)
Renaissance Technologies LLC purchased a new stake in Pacer US Cash Cows 100 ETF (BATS:COWZ – Free Report) in the...
Renaissance Technologies LLC Lowers Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)
Renaissance Technologies LLC reduced its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report) by 12.6% in...
Renaissance Technologies LLC Has $2.31 Million Position in ProShares UltraShort 20+ Year Treasury (NYSEARCA:TBT)
Renaissance Technologies LLC decreased its position in shares of ProShares UltraShort 20+ Year Treasury (NYSEARCA:TBT – Free Report) by 59.5%...
Renaissance Technologies LLC Acquires 424,678 Shares of GAN Limited (NASDAQ:GAN)
Renaissance Technologies LLC grew its holdings in shares of GAN Limited (NASDAQ:GAN – Free Report) by 51.8% in the fourth...
76,561 Shares in Schwab Fundamental Emerging Markets Large Company Index ETF (NYSEARCA:FNDE) Acquired by Renaissance Technologies LLC
Renaissance Technologies LLC bought a new position in Schwab Fundamental Emerging Markets Large Company Index ETF (NYSEARCA:FNDE – Free Report)...
Renaissance Technologies LLC Acquires Shares of 40,600 Vanguard FTSE All-World ex-US ETF (NYSEARCA:VEU)
Renaissance Technologies LLC bought a new position in shares of Vanguard FTSE All-World ex-US ETF (NYSEARCA:VEU – Free Report) during...